Several studies elucidated the distinct gene expression profiles between the AML-NK patients and refinement based on genomic aberrations such as the mutational status of prognostic genes (FLT3-ITD, CEBPA and NPM1) [17,18,19,20]. This evidence concerns the gene NPM1 and acute myeloid leukemia.